stoxline Quote Chart Rank Option Currency Glossary
Xenon Pharmaceuticals Inc. (XENE)
49.46  0.21 (0.43%)    02-23 16:00
Open: 49.21
High: 49.5099
Volume: 296,356
Pre. Close: 49.25
Low: 48.74
Market Cap: 3,655(M)
Technical analysis
2024-02-23 4:40:28 PM
Short term     
Mid term     
Targets 6-month :  59.54 1-year :  69.54
Resists First :  50.97 Second :  59.54
Pivot price 48.32
Supports First :  46.2 Second :  43.25
MAs MA(5) :  48.97 MA(20) :  47.71
MA(100) :  39.49 MA(250) :  38.64
MACD MACD :  1.2 Signal :  1.2
%K %D K(14,3) :  71.6 D(3) :  67.4
RSI RSI(14): 62.7
52-week High :  50.97 Low :  27.98
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ XENE ] has closed below upper band by 24.3%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 49.57 - 49.76 49.76 - 49.95
Low: 48.23 - 48.46 48.46 - 48.7
Close: 49.09 - 49.44 49.44 - 49.79
Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Headline News

Mon, 26 Feb 2024
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Analysts - AmericanBankingNEWS

Sun, 25 Feb 2024
Fmr LLC Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Thu, 22 Feb 2024
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 ... - TradingView

Thu, 22 Feb 2024
Rathbones Group PLC Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat

Thu, 08 Feb 2024
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks' (XENE) - Seeking Alpha

Wed, 03 Jan 2024
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Barron's

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 75 (M)
Shares Float 60 (M)
Held by Insiders 0.5 (%)
Held by Institutions 102 (%)
Shares Short 2,810 (K)
Shares Short P.Month 2,220 (K)
Stock Financials
EPS -2.67
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.78
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -17.7 %
Return on Equity (ttm) -25.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.67
Qtrly Earnings Growth 0 %
Operating Cash Flow -143 (M)
Levered Free Cash Flow -88 (M)
Stock Valuations
PE Ratio -18.6
PEG Ratio -2
Price to Book value 5.05
Price to Sales 0
Price to Cash Flow -26.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android